Targeting the Mitogen-Activated Protein Kinase Cascade to Treat Cancer

Nat Rev Cancer. 2004 Dec;4(12):937-47. doi: 10.1038/nrc1503.

Abstract

The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?

Publication types

  • Review

MeSH terms

  • Cell Cycle
  • Cell Division
  • Cell Survival
  • Enzyme Activation
  • Humans
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / chemistry
  • Mitogen-Activated Protein Kinases / metabolism*
  • Models, Molecular
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Protein Conformation
  • Signal Transduction

Substances

  • Mitogen-Activated Protein Kinases